Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Delago, D; Knittelfelder, O; Jakse, G; Lukasiak, K; Reinisch, S; Renner, W; Stranzl-Lawatsch, H; Partl, R; Langsenlehner, T.
The decreased mean platelet volume is associated with poor prognosis in patients with oropharyngeal cancer treated with radiotherapy.
Radiat Oncol. 2020; 15(1): 259-259.
Doi: 10.1186/s13014-020-01702-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Partl Richard
- Co-Autor*innen der Med Uni Graz
- Jakse Gabriele
- Langsenlehner Tanja
- Paal Katarzyna
- Reinisch Sabine
- Renner Wilfried
- Stranzl-Lawatsch Heidi
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- There is considerable evidence that platelets contribute to cancer growth and metastatic dissemination. In recent studies, altered mean platelet volume (MPV) has been associated with prognosis in different types of cancer. However, the prognostic role of the MPV in head and neck squamous cell cancer (HNSCC) is currently discussed controversially. The present study was performed to analyze and further elucidate the prognostic significance of the MPV in HNSCC. A total of 319 oropharyngeal squamous cell cancer (OPSCC) patients treated with radiotherapy at a tertiary academic center were enrolled in the present study. Kaplan-Meier method as well as uni- and multivariate Cox proportional hazards were used to evaluate the impact of MPV on cancer-specific survival (CSS), locoregional control (LC) and recurrence-free survival (RFS). The median MPV was 10.30 fL (mean 10.26 ± 1.17fL). Univariate analyses showed a significant association of the MPV with CSS (HR 0.85, 95% CI 0.74-0.98, p = 0.025), LC (HR 0.86, 95% CI 0.74-0.99, p = 0.034) and RFS (HR 0.87, 95% CI 0.76-0.996; p = 0.043). In multivariate analysis, the MPV remained an independent prognostic factor for CSS (HR 0.77, 95% CI 0.63-0.93, p = 0.008), LC (HR 0.80, 95% CI 0.65-0.98, p = 0.030), and RFS (HR 0.83, 95% CI 0.685-0.999, p = 0.049). Our findings indicate that the MPV is a prognostic marker in OPSCC patients and may contribute to future individual risk assessment.
- Find related publications in this database (Keywords)
- Oropharyngeal cancer
- Biomarker
- Mean platelet volume
- Prognostic factor
- Outcome